JCXH-108 / Immorna - LARVOL DELTA

JCXH-108-001: A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV (clinicaltrials.gov) - P1 | N=75 | Active, not recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Trial completion date: Mar 2025 ➔ Jun 2025 | Trial primary completion date: Mar 2025 ➔ Jun 2025

Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

JCXH-108-001: A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV (clinicaltrials.gov) - P1 | N=75 | Active, not recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

JCXH-108-001: A Phase 1 Study to Evaluate JCXH-108, an MRNA-based Vaccine Against RSV (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: Immorna Biotherapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV (clinicaltrials.gov) - P1 | N=75 | Not yet recruiting | Sponsor: Immorna Biotherapeutics, Inc.

New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections